Research programme: cancer immunotherapies - Asterias Biotherapeutics

Drug Profile

Research programme: cancer immunotherapies - Asterias Biotherapeutics

Alternative Names: Antigen-presenting allogeneic dendritic cells; AST-VAC2; AST-VAC2 allogeneic dendritic cell cancer vaccine - Asterias Biotherapeutics; GRNVAC 2; VAC 2

Latest Information Update: 20 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics; Cancer Research UK
  • Class Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Lung cancer
  • Discontinued Transplant rejection

Most Recent Events

  • 15 Feb 2018 Asterias Biotherapeutics has patent protection for its AST-VAC2 programme in the US, Europe, Japan, Canada, China, Australia, Israel and South Korea
  • 04 Jan 2018 Asterias and Cancer Research UK plan to conduct a phase I/IIa trial in Non-small cell lung cancer (Early-stage disease, Late stage disease, Metastatic disease, Second-line therapy or greater) in the second quarter of 2018 (NCT03371485)
  • 26 Sep 2017 Asterias Biotherapeutics receives regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the NHS Research Ethics Committee (REC) for the conduction of a phase I/IIa trial in Non-small cell lung cancer in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top